EAST WINDSOR, N.J. – Aurobindo has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for olopatadine HCl ophthalmic solution, 0.2%, 2.5 mL. Aurobindo’s olopatadine HCl ophthalmic solution is an AT-rated generic equivalent to the reference listed drug, Novartis’s Pataday Ophthalmic Solution, 0.2%.

Olopatadine HCl ophthalmic solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis. It has an estimated market size of $54M for the twelve months ending February 2019 according to IMS.